Immunitybio Inc (IBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunitybio Inc (IBRX) Stock Forecast
Analysts expect Immunitybio (IBRX) to earn -$0.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $200.30M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 127.2%.
- Fiscal year ending Dec 31, 2026
- -$0.93
- EPS consensus, revenue $200.30M
- Fiscal year ending Dec 31, 2027
- -$0.11
- EPS consensus, revenue $455.02M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.93 | -$0.93 to -$0.93 | 1 | $200.30M | $200.30M to $200.30M | 1 |
| Dec 31, 2027 | -$0.11 | -$0.32 to $0.10 | 2 | $455.02M | $316.50M to $785.70M | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.19 to -$0.07 | 6 | $57.73M | $53.21M to $61.53M | 6 |
| Mar 31, 2027 | -$0.08 | -$0.08 to -$0.08 | 1 | $69.22M | $69.22M to $69.22M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.92.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.93 | -$0.92 | -$0.92 | -$0.92 | -$0.92 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.11 | -$0.07 | -$0.14 | -$0.13 | -$0.13 | N/A |
| Quarter ending Mar 31, 2027 | -$0.08 | -$0.09 | -$0.09 | -$0.09 | N/A | N/A |
Frequently Asked Questions About IBRX
What is the IBRX stock forecast?
Consensus analyst estimates put Immunitybio's EPS at -$0.93 for the fiscal year ending Dec 31, 2026, on revenue of $200.30M. The consensus rating from 4 analysts is Buy.
How do analysts rate IBRX stock?
Of 4 analysts covering Immunitybio, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IBRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.93, with estimates from -$0.93 to -$0.93 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.11, with estimates from -$0.32 to $0.10 from 2 analysts.
What revenue do analysts expect from Immunitybio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $200.30M, with estimates from $200.30M to $200.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $455.02M, with estimates from $316.50M to $785.70M.
How many analysts cover IBRX?
4 analysts rate Immunitybio stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
IBRX pages: Overview, Earnings, Forecast, Financials, Competitors